母子Rh血型不合的孕期治疗  

Antenatal Treatment of Maternal-Fetal Rh Incompatibility Hemolysis Disease

作　　者：赵黎[1] 黄醒华[1] 王琪[1] 

机构地区：[1]北京妇产医院

出　　处：《中华妇产科杂志》1998年第7期406-408,共3页Chinese Journal of Obstetrics and Gynecology

摘　　要：目的探讨母子Ｒｈ血型不合孕期治疗的新方法。方法对５例重症Ｒｈ血型不合孕妇，在孕期除血浆去除外，同时应用静脉滴注丙种免疫球蛋白（ＩｇＧ）治疗。每次１０ｇ，并根据母体抗体滴度，间隔７～２０天１次。结果５例孕妇共滴注ＩｇＧ１２次，每例１～５次，平均每例２４次，无副作用。血浆去除共１８次，每例１～８次，平均每例３６次，无一例死胎。５例新生儿经静脉滴注ＩｇＧ和换血治疗，全部存活。结论ＩｇＧ可调整胎儿免疫能力。Objective To study the effective antenatal treatment of maternal-fetal Rh incompatibility hemolysis disease to improve fetal outcome. Methods Besides therapy of plasmapheresis, the immune globulin intravenous infusion (IVIg) was added for antenatal treatment of fetal hemolysis disease due to Rh incompatibility. Every 7～20 days 10 g IVIg was administered according to the titer of Rh antibody in maternal serum. Results 5 Rh negative pregnant women with poor obsterical history were treated with this protocol. Total IVIg infusion was 12 times with an average of 2.4 times per case, and there was no side effects. Plasmapheresis was used 18 times totally with an average of 3.6 per case. There was no fetal death. All the five newborns underwent exchange transfusion and IVIg therapy, and all were survival. Conclusion IVIg may enter fetal blood circulation via placenta, and adjust fetal immune ability to reduce the degree of fetal hemolysis.

关 键 词：RH-HR血型系统 血型不合 免疫球蛋白 孕期治疗 

分 类 号：R714.55[医药卫生—妇产科学] R722.18[医药卫生—临床医学]